Abstract

Background: Melanoma is an aggressive tumor of the skin. Drug resistance is still a major problem in melanoma therapy. Novel targets and effective agents to overcome drug resistant melanoma are urgently needed in clinical therapy. Methods: Gene Expression Omnibus (GEO) database analysis, pathway enrichment analysis, survival rate analysis were utilized to identify the candidate target. Anchorage-independent cell growth assay, flow cytometry, western blot and xenograft mouse model were conducted to study the function of AURKB in melanoma in both drug-sensitive and drug-resistant melanoma. Next, HI-511, a novel dual-target inhibitor of AURKB and BRAF V600E, was designed and confirmed by in vitro kinase assay. Anchorage-independent cell growth assay, flow cytometry. western blot, xenograft and BRAF V600E/PTEN-loss melanoma mouse models were conducted to demonstrate the effect of HI-511 on melanoma development in vitro and in vivo. Findings: AURKB is high expression in melanoma and even higher in vemurafenib-resistant melanoma, which correlated with patient's survival rate. Knocking down AURKB inhibits cells growth and induces apoptosis in melanoma, which is associated with BRAF/MEK/ERKs and PI3K/AKT signaling pathways. Importantly, we find HI-511 suppresses both vemurafenib-sensitive and vemurafenib-resistant melanoma in vitro and in vivo by inducing apoptosis and mediating the activation of BRAF/MEK/ERKs and PI3K/AKT signaling pathways. Interpretation: AURKB could be a potential target for melanoma treatment. HI-511, a novel dual-target inhibitor of both AURKB and BRAF V600E, could achieve durable suppression of melanoma, even drug-resistant melanoma. Funding Statement: This work was supported by the Hormel Foundation. Declaration of Interests: The authors declare no potential conflicts of interest. Ethics Approval Statement: All studies were performed following guidelines approved by the University of Minnesota Institutional Animal Care and Use Committee (Minneapolis, MN).

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call